




Supplemental Figures:




double heterozygotes circulating hemocytes (arrows). **m, n** Immunostaining against L1 (red) shows that nearly 10% of the lamellocytes are observable in *Gcm>jumu RNAi* circulating hemocytes. **o, p** Immunostaining against NimC1 (red) shows that NimC1 expression is reduced in *Gcm>jumu RNAi* circulating hemocytes compared with that in controls. **q** Real-time PCR analysis of phagocytosis receptor gene levels in circulating hemocytes. Error bars represent the S.E.M of at least 3 independent experiments; \*P<0.05; \*\*P<0.01; \*\*\*P<0.001 (Student's *t*-test). Scale bars: 20  $\mu$ m.




**Figure S2. Subcellular localization and expression levels of Ena, Fascin, Rho1 and Profilin in circulating hemocytes.** **a-d** Quantification of signal intensities of Ena, Fascin, Rho1 or Profilin. **e-h** Immunostaining against Ena (red), Fascin (red), Rho1 (red) or Profilin (red) and phalloidin staining (green) shows the subcellular localization of Ena, Fascin, Rho1 and Profilin in control and *jumu* mutants circulating hemocytes. Error bars represent the S.E.M of at least 3 independent experiments; \*\*P<0.01; \*\*\*P<0.001 (Student's *t*-test). Scale bars: 10  $\mu$ m.




**Figure S3. Expression levels of Profilin and Rho1 are unchanged in *jumu* or *NimC1* knockdown hemocytes.** **a** Immunostaining against Profilin (red) and Rho1 (red) in *jumu* or *NimC1* knockdown hemocytes. **b, c** Quantification of signal intensities of Profilin and Rho1. Error bars represent the S.E.M of at least 3 independent experiments; NS, not significant (Student's *t*-test). Scale bars: 20  $\mu$ m.



**Figure S4. The expression of NimC1 and the subcellular localization of Ena, Fascin, Rho1 or Profilin.** **a** Real-time PCR analysis of *NimC1* levels in circulating hemocytes. **b, c** Immunostaining against NimC1 (red) shows that NimC1 expression is unchanged in *Hml>GFP>UAS-jumu* circulating hemocytes compared with that in the controls. **d** Quantification of the signal intensities of NimC1. **e** Immunostaining against Ena, Fascin, Rho1 or Profilin and phalloidin staining (green) show the subcellular localization of Ena, Fascin, Rho1 and Profilin in control and *Hml>GFP>UAS-jumu* circulating hemocytes. Error bars represent the S.E.M of at least 3 independent experiments; NS, not significant (Student's *t*-test). Scale bars: 20  $\mu$ m (**b, c**); 10  $\mu$ m (**e**).



**Figure S5. Loss of *jumu* does not cause DNA overreplication or cell apoptosis.** **a, b** Cells in the S phase from the third-instar larval circulating hemocytes are analyzed using BrdU incorporation (red); the amount of BrdU incorporation is not increased in the *jumu* double heterozygotes compared with that in the controls. **c** Quantification of the BrdU index. **d** Quantification of phagocytic indexes of latex beads. **e-f'** Immunostaining against BrdU (green) in circulating hemocytes isolated from third-instar larvae injected with latex beads (red). **g, h** Apoptosis is analyzed through TUNEL assays in circulating cells. **i** Real-time PCR analysis of genes associated with the cell cycle and division levels of *jumu* mutant hemocytes. Error bars represent the S.E.M of at least 3 independent experiments; NS, not significant; \*\*P<0.01; \*\*\*P<0.001 (Student's *t*-test in c, I; one-way ANOVA in d). Scale bars: 20  $\mu$ m.



**Figure S6. Analysis of the activation of JAK/STAT or JNK signaling pathways.**

Real-time PCR analysis of target genes of JAK/STAT or JNK levels from *jumu* knockdown hemocytes. Error bars represent  $\pm$ S.E.M for at least 3 independent experiments; NS, not significant; \*\* $P < 0.01$ ; \*\*\* $P < 0.001$  (Student's *t*-test).